P1-233: Efficacy of carboplatin (C ) and etoposide (E ) for extensive stage small cell lung cancer (ED-SCLC)
Journal of Thoracic Oncology
Standard chemotherapy for SCLC is considered to be a cisplatin based combination. C has broad spectrum anti-tumor activity and is commonly used as a less toxic alternative to cisplatin. The purpose of this study is to investigate the activity and toxicity of C and E in patients (pts) with previously untreated ED-SCLC. Methods: Patients characteristics included pathologically diagnosed extensive SCLC, measurable or evaluable disease, ECOG performance status (PS) 0-3, and adequate organ function.
... ate organ function. Chemotherapy consisted of ( C ) AUC 6 IV day 1, ( E ) 100 mg/m 2 IV day 1-3. This schedule was repeated every 21 days for maximum 6 cycles. Data were collected prospectively. Survival data was calculated from date of treatment to date of death or last known follow up. Kaplan-Meier curves and Log Rank test were used for studying survival rates. Results: From 01/01 to 11/06, 56 Chemotherapy and radiotherapy naive pts were enrolled and 52 were evaluable. Patients characteristics were as follows: median age 62 years (range 39-76); 50 male and 2 female; ECOG PS 0-1 in 43 pts, PS 2-3 in 9 pts. 14 pts had multi-organ metastasis. 33 patients died. Seven patients lost to follow up. A total of 243 cycles were administered: median 4.68 (range 1-6). Dose reductions took place in 2.8% of cycles. The overall response rate was 71% (25% CR, 46% PR). Median overall survival was 337 days (95% [CI 272-401]), one-year and two years survival were 44.8% and 13.3%, respectively. Log Rank test demonstrated that multi-organ metastasis lead to a trend to the poor survival (P=0.055). Grade III-IV neutropenia, leukopenia, thrombocytopenia, anemia were detected in 16%, 6%, 4.5%, 3.7% of courses, respectively. Febrile neutropenia was developed in 5 patients. There was no toxic death. Non-hematological toxicity was generally mild. Conclusions: On the basis of these results, It seems that C+E is active and tolerable in ED-SCLC patients and our outcomes are in line with other published platinum-based studies.